Celularity Stock Surges 131% on $300M Manufacturing Agreement

Key Facts

1Celularity stock surged 131% following the announcement of a $300 million manufacturing collaboration.

2The agreement with MuseCell Innovations focuses on U.S. manufacturing operations in New Jersey.

In a move reflecting the rapid developments within the biotechnology sector, Celularity stock experienced an extraordinary surge during Thursday's trading session. According to reports, the share price jumped by 131% fueled by the announcement of a major manufacturing collaboration. This price rally comes as a direct response to the company's business developments, significantly boosting investor confidence in its future prospects.

The new agreement with MuseCell Innovations focuses on strengthening manufacturing operations within the United States, specifically in New Jersey, with a total value reaching $300 million. This collaboration represents a fundamental shift for Celularity, positioning it strategically to expand its production capabilities. Per analyst data, the scale of this deal relative to small-cap biotech valuations explains the massive momentum seen in the stock.

Looking at market performance, the stock recorded a powerful rally amid heavy trading; however, specific closing price levels are unavailable in the database as of August 27, 2026. Traders should monitor the sustainability of this price momentum in upcoming sessions, especially as markets await broader economic catalysts, noting that previous data showed the U.S. Services PMI reaching 56.8 points.